Canada Psilocybin Guide

Legal Status in Canada

Psilocybin and psilocin are Schedule III substances under Canada's Controlled Drugs and Substances Act (CDSA). Schedule III sits below Schedule I (heroin, cocaine) and Schedule II (cannabis was here before legalisation), placing psilocybin in a category of substances considered to have some abuse potential but also some medical value — though this category designation has not translated into routine clinical access.

Criminal penalties under the CDSA for Schedule III substances include:

• Possession — maximum 3 years imprisonment on indictment, or 6 months and/or $1,000 fine on summary conviction.
• Trafficking, importing, exporting, production — maximum 10 years imprisonment on indictment.

However, possession charges for personal amounts are rarely pursued to their maximum, and the legal landscape has been significantly disrupted by Health Canada's progressive use of exemption tools — particularly Section 56 exemptions and the Special Access Programme — creating a patchwork of legal access that is more nuanced than the statutory framework alone suggests.

Section 56 Exemptions: The Regulatory Precedent

Section 56 of the CDSA grants the federal Minister of Health the power to exempt specific individuals or activities from the scheduling provisions of the Act, "if, in the opinion of the Minister, the exemption is necessary for a medical or scientific purpose or is otherwise in the public interest."

The 2020 Precedents

In August 2020, Health Canada granted Section 56 exemptions to four terminally ill patients in British Columbia, allowing them to receive psilocybin-assisted therapy for end-of-life psychological distress. This was widely regarded as a historic decision — the first time the Canadian government had formally permitted psilocybin use in a therapeutic context in the modern era. Shortly after, exemptions were granted to therapists to access psilocybin for the purpose of training (to prepare facilitators who would guide patient sessions).

Expansion of Section 56 Use

Following the 2020 precedents, Health Canada received and granted numerous additional Section 56 applications:

• Additional palliative care patients with end-of-life distress
• Healthcare professionals seeking psilocybin training experiences under supervision
• Researchers at academic institutions

The Section 56 pathway is not a streamlined public access route — each application is reviewed individually and approval is not guaranteed. However, the pattern of approvals has established important precedents about who Health Canada considers eligible and under what circumstances.

The Special Access Programme (SAP)

The Special Access Programme (SAP) is a more formal and potentially more scalable pathway than individual Section 56 exemptions. In January 2022, Health Canada amended the SAP regulations to explicitly include restricted drugs (Schedule I, II, and III substances) such as psilocybin, making SAP access available to a broader clinical population.

How SAP Works

SAP access for psilocybin is requested by the treating healthcare practitioner (not the patient) on behalf of a specific patient. The process:

1. A licensed healthcare practitioner (physician, nurse practitioner) identifies a patient with a serious or life-threatening condition where conventional treatments have failed or are inadequate.
2. The practitioner submits a SAP application to Health Canada documenting the patient's condition, prior treatments, and clinical rationale for psilocybin.
3. Health Canada reviews the application and, if approved, issues an authorisation for the practitioner to provide psilocybin to that specific patient.
4. The practitioner must then source the psilocybin from an approved manufacturer or supplier with appropriate licences.

Who Qualifies for SAP

SAP is intended for patients with serious or life-threatening conditions including, but not limited to:

• Treatment-resistant depression (failed two or more adequate antidepressant trials)
• End-of-life anxiety and existential distress in terminal illness
• Post-traumatic stress disorder refractory to conventional treatments
• Severe anxiety disorders where other treatments have failed
• Addiction disorders where other interventions have been insufficient

SAP is not a route to recreational or wellness-oriented use — it is specifically for patients in serious clinical need. Approval is not automatic and Health Canada evaluates each application individually.

Finding a Practitioner Willing to Apply

One of the practical challenges of SAP access is finding a practitioner who is willing and able to submit an application. Many physicians are unfamiliar with the SAP process for psilocybin or are uncertain about regulatory implications. Organisations such as Therapsil (a Canadian non-profit advocating for psychedelic access) and TheraPsil maintain resources and can sometimes help patients connect with clinicians experienced in the SAP pathway.

British Columbia's Decriminalisation Experiment

British Columbia's relationship with psilocybin (and drug policy more broadly) is the most progressive of any Canadian province and represents one of the most closely watched harm-reduction experiments in North America.

The BC Federal Exemption (January 2023)

In January 2023, BC received a federal Section 56 exemption permitting personal possession of small amounts of certain drugs without criminal sanction. The exemption covered cumulative personal-use amounts up to 2.5 grams of several substances including psilocybin mushrooms. This was significant because it was the first broad personal-possession decriminalisation for psilocybin in any Canadian province.

Modification and Controversy (2024)

The BC experiment became politically contentious in 2024. Public concerns — including from some First Nations communities — about visible drug use in public spaces led the BC government to request modifications to the federal exemption. In response, the province added restrictions on where personal possession was protected (excluding public spaces such as parks and transit) and ultimately moved to rescind aspects of the broader personal possession exemption. The psilocybin-specific aspects have been less controversial than the broader opioid-related elements of the exemption, but BC's legal landscape has become more complex as a result. Verify current status with up-to-date sources.

Vancouver's Harm Reduction Philosophy

Vancouver, and particularly the Downtown Eastside neighbourhood, has been a global centre of innovative harm-reduction approaches to drug use for decades. While much of this focus has been on opioids and stimulants, the philosophical infrastructure — supervised consumption sites, peer support programmes, drug checking services — creates a model applicable to psychedelic harm reduction. The BC Centre on Substance Use (BCCSU) and organisations like Moms Stop the Harm have contributed to a harm-reduction framework that is broadly supportive of evidence-based approaches to all substances.

Canadian Research Institutions

Canada has developed one of the strongest national psychedelic research ecosystems outside the United States, supported by progressive regulatory access and significant academic interest.

University of British Columbia (UBC)

UBC researchers have contributed to psilocybin and psychedelic research, particularly through collaborations with BC's harm-reduction healthcare infrastructure. The university's proximity to Health Canada's regulatory innovations makes it well-positioned to conduct real-world studies.

McGill University (Montreal)

McGill has a strong tradition in psychopharmacology and neuroscience. Researchers at McGill's Department of Psychiatry and affiliated institutions have conducted studies on psilocybin's mechanisms of action and therapeutic applications, with particular interest in the intersection of psychedelic states and consciousness research.

University of Toronto

University of Toronto researchers have conducted clinical studies on psilocybin for addiction (smoking cessation and alcohol use disorder) and depression. The Centre for Addiction and Mental Health (CAMH), Toronto's major psychiatric research hospital, has been at the forefront of psychedelic therapy research in Canada and has hosted Health Canada-approved psilocybin research trials.

Queen's University (Kingston)

Queen's has researchers involved in the study of altered states of consciousness and psychedelic therapy, with active clinical research programmes.

University of Calgary

Researchers at the University of Calgary's Department of Clinical Neurosciences have conducted studies on psilocybin for treatment-resistant depression and other applications.

How to Apply for SAP Access: A Practical Overview

For Canadian patients and healthcare providers considering the SAP pathway:

1. Confirm clinical eligibility — you (or your patient) must have a serious or life-threatening condition for which conventional treatments have been tried and failed or are not appropriate. Obtain documentation of treatment history.
2. Find a willing practitioner — the application must come from a licensed healthcare practitioner. If your current physician is unfamiliar with SAP for psilocybin, organisations such as Therapsil (therapsil.ca) maintain lists of practitioners with SAP experience.
3. Gather documentation — the SAP application requires clinical documentation of the patient's history, diagnosis, prior treatments, and the rationale for psilocybin. The practitioner's team typically prepares this.
4. Submit the SAP application — applications are submitted to Health Canada's Health Products and Food Branch. Processing times vary; some applications receive expedited review for urgent cases.
5. Await Health Canada decision — approval is not guaranteed. Health Canada may request additional information before making a decision.
6. Source approved psilocybin — if approved, the practitioner must obtain psilocybin from a licensed manufacturer or supplier. Currently operating licensed Canadian suppliers include companies that have been granted Health Canada production licences.
7. Conduct the therapy — sessions should be conducted in a medically supervised setting with appropriate preparation and integration support.

Therapsil provides advocacy and practical support for patients and practitioners navigating the SAP process and is one of the most important non-governmental organisations in Canadian psychedelic access.

The Underground Therapy Scene in Canada

Alongside the formal regulated access pathways, Canada has a substantial underground psilocybin therapy scene. This reality is acknowledged by harm-reduction advocates and researchers even as it exists outside legal boundaries.

Underground facilitators and therapists have been providing psilocybin-assisted sessions in Canada — primarily in major cities — for years, drawing on therapeutic models developed in research and retreat settings. These practitioners operate outside Health Canada's regulatory framework and without formal legal authorisation.

Harm-reduction context for people considering underground therapy:

• There is no regulatory quality control for underground psilocybin sessions. Vetting the facilitator's training, ethics, and track record is entirely the participant's responsibility.
• There is no formal accountability mechanism if something goes wrong.
• Practitioner training varies enormously — from deep, legitimate training in established therapeutic traditions to minimal or none.
• Despite the risks, research suggests that many underground sessions are conducted safely by experienced facilitators, and this reality informs harm-reduction approaches.
• If you are considering underground therapy, ask detailed questions about the facilitator's training, supervision, approach to screening, and what happens in difficult situations. A reputable facilitator will welcome these questions.
• The Zendo Project and Fireside Project provide support resources applicable to any psilocybin experience regardless of its legal context.

Indigenous Ceremonial Contexts in Canada

Canada's Indigenous peoples have long relationships with plant medicines within ceremonial and healing traditions. The legal and cultural dimensions of this are complex:

• Canada's CDSA does not provide an explicit blanket exemption for Indigenous ceremonial use of psilocybin mushrooms (unlike the US federal exemption for peyote in Native American Church contexts).
• However, Section 35 of the Constitution Act 1982 recognises and affirms existing Aboriginal and treaty rights, and the duty to consult and accommodate Indigenous peoples in federal decision-making is a constitutional obligation.
• Health Canada has a responsibility to consult with Indigenous communities on psilocybin regulations, and some advocacy specifically addresses the need to protect Indigenous ceremonial access to plant medicines including psilocybin-containing mushrooms.
• The Secwepemc Nation and other First Nations have made public statements about the significance of plant medicines in their healing traditions and the need for policy reform to recognise this.
• In practice, ceremonial use in Indigenous contexts is typically not the subject of active enforcement, though this does not constitute formal legal protection.

Non-Indigenous Canadians should be thoughtful about cultural context and not conflate access to Indigenous ceremonies with personal use rights.

Province-by-Province Enforcement Differences

While the CDSA is federal legislation and applies uniformly across Canada, enforcement is handled by provincial and municipal police forces, and there are meaningful differences in prosecution philosophy and practice across provinces.

Province / Territory	Notable Characteristics
British Columbia	Most progressive harm-reduction approach; personal possession exemption (for limited amounts, with ongoing changes); lowest prosecution rates; Vancouver's harm-reduction infrastructure.
Ontario	Major research hub (CAMH, U of T); Toronto has a significant underground therapy scene; enforcement varies by municipality; Crown prosecution of personal possession is relatively rare in major cities.
Quebec	Montreal has active psychedelic research (McGill) and a substantial harm-reduction culture; civil-law legal system creates different prosecutorial dynamics.
Alberta	More conservative enforcement tradition; fewer harm-reduction services; Calgary has emerging research programmes. Edmonton harm-reduction services have expanded.
Atlantic Provinces (NS, NB, PEI, NL)	Smaller populations; less active psychedelic research scene; enforcement varies; rural contexts may differ from urban.
Prairie Provinces (MB, SK)	More conservative drug enforcement traditions in some areas; Winnipeg has active harm-reduction services for other substances that create relevant infrastructure.
Territories (YT, NT, NU)	Remote geography; enforcement resource constraints; Indigenous community context is significant across all three territories.

Timeline of Canadian Psilocybin Reforms

Date	Development
August 2020	Health Canada grants Section 56 exemptions to four terminal patients for psilocybin-assisted therapy — first such exemptions in modern Canadian history.
2020–2021	Exemptions granted to healthcare practitioners for training purposes; SAP exemption applications begin to be reviewed.
January 2022	Health Canada amends SAP regulations to include restricted drugs (including psilocybin), formalising a pathway for clinical access.
2022	Multiple Canadian universities receive Health Canada licences for psilocybin research; CAMH begins formal clinical programmes.
January 2023	BC receives federal exemption for personal drug possession including psilocybin mushrooms (up to 2.5g); first provincial-level personal decriminalisation in Canadian history.
2024	BC modifies personal possession exemption amid public controversy; psilocybin remains in complex regulatory position within BC; SAP approvals continue nationally.
2025–2026	Ongoing expansion of research programmes; growing advocacy for formal regulated therapeutic access model; Health Canada consultation on psychedelic frameworks.

Integration Therapists in Canada

Integration support is available from an increasing number of Canadian therapists and counsellors, particularly in major cities. Integration therapy involves helping people make sense of and apply insights from a psilocybin experience — it does not involve facilitating or administering any substance.

Finding integration support in Canada:

• Psychedelic Support Finder (finder.psychedelicsupport.com) — directory with Canadian listings; search by province.
• Therapsil provider network (therapsil.ca) — Therapsil has worked to connect patients with clinicians and can sometimes assist with integration referrals.
• Psychology Today Canada — therapist directory allowing search by specialism; "transpersonal therapy" and "psychedelic" as keywords may identify relevant practitioners.
• MAPS Canada — the Canadian arm of MAPS maintains networks of trained practitioners and can provide referrals.

When seeking integration support, confirm the therapist is registered with their provincial regulatory college (e.g., College of Registered Psychotherapists of Ontario, BC College of Social Workers) to ensure professional accountability.

Harm Reduction for Canadians

For Canadians who choose to use psilocybin outside of approved programmes, the following harm-reduction guidance applies:

Health Contraindications

• Personal or family history of psychosis, schizophrenia, or bipolar I disorder — significant risk of precipitating or worsening psychotic episodes. Do not use.
• Lithium — do not combine; risk of seizures has been documented.
• MAOIs — potentially dangerous serotonergic interaction; do not combine.
• Cardiac conditions — psilocybin temporarily elevates heart rate and blood pressure; consult a physician if you have cardiac disease.
• Pregnancy or breastfeeding — insufficient safety data; avoid.

Practical Safety

• Know your source. Canadian law prevents regulated testing of psilocybin products sold informally. Mushroom misidentification is a genuine risk for wild-foraged fungi.
• Start with a low dose if inexperienced (0.5–1g dried mushrooms or equivalent).
• Use set and setting intentionally — quiet, familiar, safe environment with clear intentions.
• Have a trusted, sober sitter for any dose above microdose level.
• Do not drive for at least 6–8 hours after any significant dose.
• Avoid alcohol, cannabis, and other substances during and after the experience.
• Have a plan for integration — the days following a psilocybin experience are as important as the experience itself.

If Things Go Difficult

• Fireside Project — +1-623-473-7433 — free, non-judgmental psychedelic peer support available by call or text during or after a difficult experience. Open to Canadian callers.
• Crisis services — if there are genuine safety concerns, Canadian 911 emergency services and hospital emergency departments are available. Be honest with medical staff about what was taken. Canadian healthcare providers prioritise patient welfare over law enforcement involvement for personal-use amounts.
• Integration support post-difficult experience — difficult psilocybin experiences can generate lasting psychological material that benefits from professional support. A trauma-informed therapist experienced with psychedelic material is ideal; the Psychedelic Support finder can identify Canadian practitioners.

Further Information

For broader North American context, see our North America Psilocybin Guide. For US state programmes, see our Oregon and Colorado guides. For general safety guidance, visit our Safety & Harm Reduction section. For general legal comparisons, visit our Legal Status Guide.